I took a look at the study and the supplementary data. They tested for multiple variations of CD4+ and CD8+ T-cells. Yet knowing that there is immune dysfunction they never bothered to test for levels of CCR5. I also noticed that the p values showed very few differences between controls and ME/CSF patients. Which is understandable given the low number of study participants. With the low number of people in the study the FDA would consider this not a landmark but garbage. In our Long Covid and even in the Montefiore results leronlimab was showing the wide contrasts in p values.

https://www.nature.com/articles/s41467-024-45107-3#MOESM4

The NIH has failed woefully.

Quote:

---

‘Underwhelming’: NIH trials fail to test meaningful long Covid treatments — after 2.5 years and $1 billion

About 15% of the funding — $171.5 million — went to clinical trials, under the leadership of Duke University’s Clinical Research Institute. Meanwhile, the NIH allocated the vast majority of its funds to research aimed at better understanding long Covid symptoms, according to the budget document. This includes $537 million to set up and study patient cohorts, $149 million for studying biological samples and health records, $122 million for following patients in the future and $56 million for administrative tasks provided by consulting firms RTI International and Deloitte.
https://www.statnews.com/2023/08/09/long-covid-nih-trials/

---